Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose rt-PA for Pulmonary Thromboembolism in China
NCT00781378Phase 4Completed
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Jun 2002
- Primary completion
- Feb 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Improvement of right ventricular function on echocardiograms at 14 days, Perfusion defect score of lung V/Q scans at 14 days and 1 more. Started Jun 2002; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00781378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781378.